The box is on the porch. The video call ran two minutes, maybe less, and then a chat window opened with a reply that could have been written for anyone.
That is the version of care a lot of people describe after they have already paid. They typed “best GLP-1 telehealth” into a search bar because they wanted a clinic. What arrived was a questionnaire, a shipment, and silence once the scale stopped moving.
Some programs sell speed as if speed were the same thing as looking after you. Fill the form, wait for the carrier. The medicine in the vial may be real. What is missing is the relationship, the part you actually needed when the nausea hit on a Tuesday night.
I have been reading the public complaint record for this market instead of the ads, counting one-star and two-star reviews and complaint pages by hand. The sample is not a census. Angry people post, and people who are fine mostly stay quiet. Even with that bias, one line keeps landing in the same words.
They could not reach a human.
They mention a chatbot, a missed appointment, a phone that rang until it died. They paid, and then the box came, or it sat in a warehouse while the calendar kept moving. When the dose that felt fine last month suddenly did not, they needed someone who had actually read their file. They got a ticket number.
No lab result captures that feeling. It is the sense that the system failed them, and they are not being precious about it.
The FDA has already named a version of this as a consumer red flag. Watch for a company that does not require a screening and a prescription from a licensed doctor before sending medicine. Watch for a company that has no licensed doctor available to answer questions after the medicine arrives.
After the box. That is the part a lot of these services skip. Follow-up takes staff and time, and a chatbot is cheaper than either.
Ongoing care is the part that costs money, and it is the first thing a thin program cuts.
What ongoing care is supposed to include
Obesity is a chronic disease, not a two-week project with a tracking number. The federal guidance is blunt that weight-management medicines do not replace eating habits or physical activity. They work best as part of a plan a clinician is still watching months later.
A real intake comes first: your history, your other medicines, the conditions that change your risk, and a licensed clinician deciding whether a GLP-1 belongs in your life at all. If that step is a four-minute form on your phone, no one has really screened you. You have checked out and paid.
Dose review is next, and it should take time. The approved weekly semaglutide product for weight reduction starts low and steps the dose up about every four weeks. A clinician is meant to watch how you handle each step, whether that is nausea, a stall, or a jump that came too fast. Compounded copies of these drugs are not FDA-approved, and they are not the same as the brand-name pens. That does not make dose review optional. It makes it more necessary, because the vial in your fridge did not go through the same premarket check.
The agency has already seen what happens when nobody teaches the injection. The FDA has reported adverse events, some of them hospitalizations, tied to dosing errors with compounded injectable semaglutide. Some people had never drawn medicine from a vial. Units got mixed up with milligrams. Regulators told providers to counsel patients on how to measure the intended dose. That is teaching, not a PDF buried three taps deep in an app you have stopped opening.
Then there are the check-ins, and this is where the numbers get loud. In commercial insurance data on nearly 170,000 members, Blue Health Intelligence found that 58 percent of people stopped GLP-1s before a clinically meaningful benefit. Thirty percent stopped in the first month. People who got the prescription from an endocrinologist or an obesity-medicine specialist were more likely to stay on. So were people who saw their doctor more often, in any specialty.
That is not about personality. It comes down to contact. A medicine meant to be titrated over months cannot be run by a calendar reminder and a shrug.
Someone to ask when the scale stops is the piece people describe as missing, and it is the piece that turns a subscription into care. The federal guidance tells clinicians to look again if you have not lost at least 5 percent of your starting weight after 12 weeks on the full dose. The next move might be a different plan, a different medicine, or a hard look at other drugs that can add weight. It might be a talk about sleep, or a week the water won. Whatever it turns out to be, it beats an automated note that says hang in there.
What people mean by the best telehealth
They do not mean the fastest box. They mean a clinic that still knows their name in month four, when the novelty is gone and the scale has gotten rude.
Living+ is built for that slower work. Compounded semaglutide is 197 dollars a month and compounded tirzepatide is 247, both flat, each with a personal coach. There is no separate visit fee, and the price does not climb when your dose does. If a clinician declines you, the charge is refunded.
A coach is not a miracle, and not a promise that the scale will move. Some people do well on these medicines. Some stop because of cost, or nausea, or a life that will not hold still. The point of a real person on the plan is that you are not left alone with a vial and a guess about the next milligram.
Talk to your provider, ours or anyone’s. Ask who you actually reach when the number freezes, how often someone reviews your dose, and what happens if you feel awful after dinner. If the honest answer is that you open a ticket, you already know what kind of program you bought.
The porch will keep getting packages. The question worth asking is whether anyone is still on the line after you cut the tape.
Prices were accurate at the time this was published.
Sources
- FDA: semaglutide for weight loss, consumer red flags
- NIDDK: prescription medications to treat overweight and obesity
- FDA: compounding questions and answers
- FDA alert: dosing errors with compounded injectable semaglutide
- Blue Health Intelligence study: most patients stop GLP-1s before benefit
See what a Living+ plan costs and whether it fits.
